Ivonescimab (SMT112 or AK112) Injection

DRUG3 trials

Sponsors

Akeso, The First Affiliated Hospital of Zhengzhou University

Conditions

Locally Advanced Rectal CancerNon-Squamous Non-small Cell Lung CancerPancreas CancerPancreas Cancer, Duct Cell Adenocarcinoma

Phase 1

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Not yet recruitingNCT06913218

AkesoPancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma

Start: 2025-07-22End: 2028-11-06Target: 60Updated: 2025-04-06

Phase 2

Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer

Not yet recruitingNCT06760520

The First Affiliated Hospital of Zhengzhou UniversityLocally Advanced Rectal Cancer

Start: 2025-01-20End: 2031-12-20Target: 40Updated: 2025-01-08

Phase 3

Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruitingNCT05184712

AkesoNon-Squamous Non-small Cell Lung Cancer

Start: 2022-01-25End: 2026-09-01Updated: 2026-03-04

Related Papers

Ivonescimab plus chemotherapy in advanced or metastatic non‑squamous non‑small cell lung cancer with EGFR variant in China: a cost-effectiveness analysis.

2025-05-22

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.

Journal of Clinical Oncology2024-06-0111 citations

Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant

JAMA2024-05-31121 citations

Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2024-04-0147 citations

AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.

2023-08-0361 citations